TY - JOUR
T1 - Soft, skin-interfaced sweat stickers for cystic fibrosis diagnosis and management
AU - Ray, Tyler R.
AU - Ivanovic, Maja
AU - Curtis, Paul M.
AU - Franklin, Daniel
AU - Guventurk, Kerem
AU - Jeang, William J.
AU - Chafetz, Joseph
AU - Gaertner, Hannah
AU - Young, Grace
AU - Rebollo, Steve
AU - Model, Jeffrey B.
AU - Lee, Stephen P.
AU - Ciraldo, John
AU - Reeder, Jonathan T.
AU - Hourlier-Fargette, Aurélie
AU - Bandodkar, Amay J.
AU - Choi, Jungil
AU - Aranyosi, Alexander J.
AU - Ghaffari, Roozbeh
AU - McColley, Susanna A.
AU - Haymond, Shannon
AU - Rogers, John A.
N1 - Publisher Copyright:
Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works
PY - 2021/3/31
Y1 - 2021/3/31
N2 - The concentration of chloride in sweat remains the most robust biomarker for confirmatory diagnosis of cystic fibrosis (CF), a common life-shortening genetic disorder. Early diagnosis via quantitative assessment of sweat chloride allows prompt initiation of care and is critically important to extend life expectancy and improve quality of life. The collection and analysis of sweat using conventional wrist-strapped devices and iontophoresis can be cumbersome, particularly for infants with fragile skin, who often have insufficient sweat production. Here, we introduce a soft, epidermal microfluidic device (“sweat sticker”) designed for the simple and rapid collection and analysis of sweat. Intimate, conformal coupling with the skin supports nearly perfect efficiency in sweat collection without leakage. Real-time image analysis of chloride reagents allows for quantitative assessment of chloride concentrations using a smartphone camera, without requiring extraction of sweat or external analysis. Clinical validation studies involving patients with CF and healthy subjects, across a spectrum of age groups, support clinical equivalence compared to existing device platforms in terms of accuracy and demonstrate meaningful reductions in rates of leakage. The wearable microfluidic technologies and smartphone-based analytics reported here establish the foundation for diagnosis of CF outside of clinical settings.
AB - The concentration of chloride in sweat remains the most robust biomarker for confirmatory diagnosis of cystic fibrosis (CF), a common life-shortening genetic disorder. Early diagnosis via quantitative assessment of sweat chloride allows prompt initiation of care and is critically important to extend life expectancy and improve quality of life. The collection and analysis of sweat using conventional wrist-strapped devices and iontophoresis can be cumbersome, particularly for infants with fragile skin, who often have insufficient sweat production. Here, we introduce a soft, epidermal microfluidic device (“sweat sticker”) designed for the simple and rapid collection and analysis of sweat. Intimate, conformal coupling with the skin supports nearly perfect efficiency in sweat collection without leakage. Real-time image analysis of chloride reagents allows for quantitative assessment of chloride concentrations using a smartphone camera, without requiring extraction of sweat or external analysis. Clinical validation studies involving patients with CF and healthy subjects, across a spectrum of age groups, support clinical equivalence compared to existing device platforms in terms of accuracy and demonstrate meaningful reductions in rates of leakage. The wearable microfluidic technologies and smartphone-based analytics reported here establish the foundation for diagnosis of CF outside of clinical settings.
UR - http://www.scopus.com/inward/record.url?scp=85103620338&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103620338&partnerID=8YFLogxK
U2 - 10.1126/scitranslmed.abd8109
DO - 10.1126/scitranslmed.abd8109
M3 - Article
C2 - 33790027
AN - SCOPUS:85103620338
SN - 1946-6234
VL - 13
JO - Science Translational Medicine
JF - Science Translational Medicine
IS - 587
M1 - e8109
ER -